CA2559203A1 - Phenylethanolamine derivatives as beta-2 agonists - Google Patents

Phenylethanolamine derivatives as beta-2 agonists Download PDF

Info

Publication number
CA2559203A1
CA2559203A1 CA002559203A CA2559203A CA2559203A1 CA 2559203 A1 CA2559203 A1 CA 2559203A1 CA 002559203 A CA002559203 A CA 002559203A CA 2559203 A CA2559203 A CA 2559203A CA 2559203 A1 CA2559203 A1 CA 2559203A1
Authority
CA
Canada
Prior art keywords
hydroxy
phenyl
ethyl
hydroxymethyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002559203A
Other languages
English (en)
French (fr)
Inventor
Alan Daniel Brown
Mark Edward Bunnage
Paul Alan Glossop
Kim James
Charlotte Alice Louise Lane
Russell Andrew Lewthwaite
Graham Lunn
David Anthony Price
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc.
Alan Daniel Brown
Mark Edward Bunnage
Paul Alan Glossop
Kim James
Charlotte Alice Louise Lane
Russell Andrew Lewthwaite
Graham Lunn
David Anthony Price
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04290725A external-priority patent/EP1577291A1/en
Priority claimed from GB0425064A external-priority patent/GB0425064D0/en
Application filed by Pfizer Inc., Alan Daniel Brown, Mark Edward Bunnage, Paul Alan Glossop, Kim James, Charlotte Alice Louise Lane, Russell Andrew Lewthwaite, Graham Lunn, David Anthony Price, Pfizer Limited filed Critical Pfizer Inc.
Publication of CA2559203A1 publication Critical patent/CA2559203A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002559203A 2004-03-17 2005-03-10 Phenylethanolamine derivatives as beta-2 agonists Abandoned CA2559203A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP04290725.3 2004-03-17
EP04290725A EP1577291A1 (en) 2004-03-17 2004-03-17 Phenylethanolamine derivatives as beta-2 agonists
US59179004P 2004-07-27 2004-07-27
US60/591,790 2004-07-27
GB0425064.3 2004-11-12
GB0425064A GB0425064D0 (en) 2004-11-12 2004-11-12 Compounds useful for the treatment of diseases
PCT/IB2005/000640 WO2005090287A2 (en) 2004-03-17 2005-03-10 Phenylethanolamine derivatives as beta-2 agonists

Publications (1)

Publication Number Publication Date
CA2559203A1 true CA2559203A1 (en) 2005-09-29

Family

ID=56290672

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002559203A Abandoned CA2559203A1 (en) 2004-03-17 2005-03-10 Phenylethanolamine derivatives as beta-2 agonists

Country Status (7)

Country Link
EP (1) EP1727789A2 (ru)
JP (1) JP4054366B2 (ru)
AU (1) AU2005223488A1 (ru)
BR (1) BRPI0508927A (ru)
CA (1) CA2559203A1 (ru)
EA (1) EA200601510A1 (ru)
WO (1) WO2005090287A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425054D0 (en) * 2004-03-23 2004-12-15 Pfizer Ltd Formamide derivatives for the treatment of diseases
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
CN116033893A (zh) 2020-06-26 2023-04-28 迈兰制药英国有限公司 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1529972A (en) * 1975-07-29 1978-10-25 Allen & Hanburys Ltd Basic alcohols
DE2965655D1 (en) * 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
NL8501124A (nl) * 1984-04-17 1985-11-18 Glaxo Group Ltd Fenethanolamine-verbindingen, de bereiding daarvan, alsmede farmaceutische preparaten waarvan zij een component vormen.
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
OA11558A (en) * 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
WO2003042160A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
ATE381535T1 (de) * 2002-04-25 2008-01-15 Glaxo Group Ltd Phenethanolaminderivate
EP1477167A1 (en) * 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists

Also Published As

Publication number Publication date
AU2005223488A1 (en) 2005-09-29
JP4054366B2 (ja) 2008-02-27
WO2005090287A3 (en) 2006-02-16
WO2005090287A2 (en) 2005-09-29
BRPI0508927A (pt) 2007-08-14
EP1727789A2 (en) 2006-12-06
JP2007529501A (ja) 2007-10-25
EA200601510A1 (ru) 2007-04-27

Similar Documents

Publication Publication Date Title
EP1730103B1 (en) Formamide derivatives useful as adrenoceptor
EP1730141B1 (en) Compounds for the treatment of diseases
US7482487B2 (en) Phenylaminoethanol derivatives as β2 receptor agonists
US7268147B2 (en) Compounds useful for the treatment of diseases
CA2559203A1 (en) Phenylethanolamine derivatives as beta-2 agonists
WO2005092861A1 (en) Quinolinone derivatives pharmaceutical compositions containing them and their use
EP1624868B1 (en) "(2-hydroxy-2-(4-hydroxy-3-hydoxymethylphenyl)-ethylamino)- propyl]phenyl derivatives as beta2 agonists
WO2005092841A1 (en) Compounds having beta-agonist activity
AU2005214154A1 (en) Sulfonamide derivatives for the treatment of diseases
WO2006051373A1 (en) Compounds for the treatment of diseases
WO2005092860A1 (en) Compounds for the treatment of diseases
US20050215542A1 (en) Compounds for the treatment of diseases
US7538141B2 (en) Compounds for the treatment of diseases
EP1577291A1 (en) Phenylethanolamine derivatives as beta-2 agonists
EP1574501A1 (en) Quinolinone derivatives, pharmaceutical compositions containing them and their use
US7629358B2 (en) Compounds useful for the treatment of diseases
CA2560547C (en) Formamide derivatives useful as adrenoceptor
NL1028559C2 (nl) Verbindingen die bruikbaar zijn voor de behandeling van ziekten
MXPA06009533A (en) Compounds for the treatment of diseases
MXPA06010257A (en) Compounds useful for the treatment of diseases

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead